Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK

Dow Jones11-21 22:30

By Ben Glickman

Shares of Zymeworks rose early Thursday after the cancer therapy it is developing with Jazz Pharmaceuticals received accelerated regulatory approval for treating forms of biliary tract cancer.

Zymeworks' stock was up 8.3% to $15.75 in pre-market trading. Shares are up about 40% this year as of Wednesday's close.

The U.S. Food and Drug Administration granted Ziihera, an antibody treatment, accelerated approval for injection for intravenous use in treating adults with certain forms of biliary tract cancer.

Zymeworks first developed the molecule, and in 2022 entered a license and collaboration deal with Jazz for exclusive development and commercialization rights to the compound in most countries. Under the licensing deal, Zymeworks has earned a milestone payment of $25 million based on FDA approval of Ziihera in BTC.

Jazz shares were up about 2.3% in pre-market trading.

BeiGene has the compound's license in Asia Pacific territories.

The company is still eligible for up to $500 million in regulatory milestone payments and $862.5 million in commercial milestone payments from Jazz. Zymeworks will also receive tiered royalties on sales.

Zymeworks said Ziihera was the first candidate in its pipeline to receive FDA approval.

Ziihera, known by generic name zanidatamab, is also being evaluated as a treatment option for patients with other solid tumors.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

November 21, 2024 09:30 ET (14:30 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485963492?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-21 22:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485963492","market":"sg","top_or_hot":-1,"title":"Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Ben Glickman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Zymeworks rose early Thursday after the cancer therapy it is developing with Jazz Pharmaceuticals received accelerated regulatory approval for treating forms of biliary tract cancer. \n</p>\n<p>\n  Zymeworks' stock was up 8.3% to $15.75 in pre-market trading. Shares are up about 40% this year as of Wednesday's close. \n</p>\n<p>\n  The U.S. Food and Drug Administration granted Ziihera, an antibody treatment, accelerated approval for injection for intravenous use in treating adults with certain forms of biliary tract cancer. \n</p>\n<p>\n  Zymeworks first developed the molecule, and in 2022 entered a license and collaboration deal with Jazz for exclusive development and commercialization rights to the compound in most countries. Under the licensing deal, Zymeworks has earned a milestone payment of $25 million based on FDA approval of Ziihera in BTC. \n</p>\n<p>\n  Jazz shares were up about 2.3% in pre-market trading. \n</p>\n<p>\n  BeiGene has the compound's license in Asia Pacific territories. \n</p>\n<p>\n  The company is still eligible for up to $500 million in regulatory milestone payments and $862.5 million in commercial milestone payments from Jazz. Zymeworks will also receive tiered royalties on sales. \n</p>\n<p>\n  Zymeworks said Ziihera was the first candidate in its pipeline to receive FDA approval. \n</p>\n<p>\n  Ziihera, known by generic name zanidatamab, is also being evaluated as a treatment option for patients with other solid tumors. \n</p>\n<pre>\n \n</pre>\n<p>\n   Write to Ben Glickman at ben.glickman@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 21, 2024 09:30 ET (14:30 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-21 22:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Ben Glickman \n\n\n \n\n\n  Shares of Zymeworks rose early Thursday after the cancer therapy it is developing with Jazz Pharmaceuticals received accelerated regulatory approval for treating forms of ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2485963492","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485963492","pubTimestamp":1732199400,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Zymeworks rose early Thursday after the cancer therapy it is developing with Jazz Pharmaceuticals received accelerated regulatory approval for treating forms of biliary tract cancer.Zymeworks' stock was up 8.3% to $15.75 in pre-market trading. Shares are up about 40% this year as of Wednesday's close.The U.S. Food and Drug Administration granted Ziihera, an antibody treatment, accelerated approval for injection for intravenous use in treating adults with certain forms of biliary tract cancer.Zymeworks first developed the molecule, and in 2022 entered a license and collaboration deal with Jazz for exclusive development and commercialization rights to the compound in most countries. Under the licensing deal, Zymeworks has earned a milestone payment of $25 million based on FDA approval of Ziihera in BTC.Jazz shares were up about 2.3% in pre-market trading.BeiGene has the compound's license in Asia Pacific territories.Zymeworks said Ziihera was the first candidate in its pipeline","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","JAZZ":"爵士制药","BK4139":"生物科技","BK4504":"桥水持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","ZYME":"ZYMEWORKS INC (US)","BK4588":"碎股","BK4007":"制药","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4526":"热门中概股","BK4505":"高瓴资本持仓","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BGNE":"百济神州","BK4585":"ETF&股票定投概念"},"translate_title":"癌症治疗许可获得FDA批准后，Zymeworks股价上涨8.3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZYME":0.9,"JAZZ":0.9,"BGNE":0.9},"content_text":"By Ben Glickman \n\n\n \n\n\n  Shares of Zymeworks rose early Thursday after the cancer therapy it is developing with Jazz Pharmaceuticals received accelerated regulatory approval for treating forms of biliary tract cancer. \n\n\n  Zymeworks' stock was up 8.3% to $15.75 in pre-market trading. Shares are up about 40% this year as of Wednesday's close. \n\n\n  The U.S. Food and Drug Administration granted Ziihera, an antibody treatment, accelerated approval for injection for intravenous use in treating adults with certain forms of biliary tract cancer. \n\n\n  Zymeworks first developed the molecule, and in 2022 entered a license and collaboration deal with Jazz for exclusive development and commercialization rights to the compound in most countries. Under the licensing deal, Zymeworks has earned a milestone payment of $25 million based on FDA approval of Ziihera in BTC. \n\n\n  Jazz shares were up about 2.3% in pre-market trading. \n\n\n  BeiGene has the compound's license in Asia Pacific territories. \n\n\n  The company is still eligible for up to $500 million in regulatory milestone payments and $862.5 million in commercial milestone payments from Jazz. Zymeworks will also receive tiered royalties on sales. \n\n\n  Zymeworks said Ziihera was the first candidate in its pipeline to receive FDA approval. \n\n\n  Ziihera, known by generic name zanidatamab, is also being evaluated as a treatment option for patients with other solid tumors. \n\n\n \n\n\n   Write to Ben Glickman at ben.glickman@wsj.com \n\n\n  (END) Dow Jones Newswires\n\n\n  November 21, 2024 09:30 ET (14:30 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485963492"}